<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26466072</article-id>
      <article-id pub-id-type="pmc">4592180</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20150119</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Anatomopathological Session</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case 3/2015 &#x2013; 53-Year-Old Female with Cardiogenic Shock 12 Years after
Surgical Correction of Endomyocardial Fibrosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ponczek</surname>
            <given-names>Michel Abi Kalansky</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Feitosa</surname>
            <given-names>Fernanda Seligmann</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Demarchi</surname>
            <given-names>L&#xE9;a Maria Macruz Ferreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">Instituto do Cora&#xE7;&#xE3;o (InCor) &#x2013; HC-FMUSP, S&#xE3;o Paulo, SP &#x2013; Brazil</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing Address: Vera Demarchi Aiello</bold>, Avenida Dr. En&#xE9;as
de Carvalho Aguiar, 44, subsolo, bloco I, Cerqueira C&#xE9;sar. Postal Code 05403-000, S&#xE3;o
Paulo, SP &#x2013; Brazil. E-mail: <email>demarchi@cardiol.br</email>,
<email>vera.aiello@incor.usp.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <volume>105</volume>
      <issue>3</issue>
      <fpage>309</fpage>
      <lpage>315</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Choque Cardiog&#xEA;nico</kwd>
        <kwd>Fibrose Endomioc&#xE1;rdica / cirurgia</kwd>
        <kwd>Arritmias Card&#xED;acas</kwd>
        <kwd>Marca-Passo Artificial</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>A 53-year-old female, submitted to surgical correction of endomyocardial fibrosis (EMF) 12
years before, sought medical care with hypotension and bradycardia.</p>
    <p>She complained of palpitations since the age of 29 years. Her symptoms aggravated 5 years
later, with the appearance of dyspnea on moderate exertion. After 5 more years, the dyspnea
intensified, being triggered on mild exertion and in the dorsal decubitus position. The
patient was then referred to a hospital.</p>
    <p>In 1994, the physical examination revealed irregular pulse, heart rate of 88 bpm, blood
pressure of 104/80 mm Hg, and increased jugular venous pressure. The pulmonary exam was
normal, and the heart auscultation showed arrhythmic heart sounds and mitral systolic
murmur (+/4). The exam of the abdomen and limbs was within the normal range.</p>
    <p>In February 1994, the electrocardiogram (ECG) showed atrial fibrillation, left
bundle-branch block and left ventricular hypertrophy (<xref ref-type="fig" rid="f01">Figure
1</xref>).</p>
    <fig id="f01" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>ECG: Atrial fibrillation, left bundle-branch block and left ventricular
hypertrophy.</p>
      </caption>
      <graphic xlink:href="abc-105-03-0309-g01"/>
    </fig>
    <p>In 1996, on echocardiogram, the dimensions of the cardiac chambers were: left atrium, 57
mm; left ventricle, 51 mm (diastole) and 33 mm (systole). Obliteration of the apical region
of both ventricles was observed, with suggestive signs of calcification. The morphological
aspect was considered suggestive of EMF.</p>
    <p>In 1996, a ventriculography showed obliteration of the apical region of left and right
ventricles, in addition to mild mitral regurgitation. On coronary cineangiography, the
circumflex branch of the left coronary artery originated from the right coronary artery. No
obstruction of the coronary arteries was identified. The ventriculography findings were
suggestive of EMF.</p>
    <p>Surgical treatment was indicated.</p>
    <p>In September 1996 the surgery was performed with incision in the apical region of the left
ventricle and resection of a fibrous and calcified mass. Then, through the interatrial
septum, annuloplasty with bovine pericardium was performed in the posterior portion of the
mitral ring and in the anterior portion of the tricuspid ring.</p>
    <p>The control ventriculography one month after surgery showed mild left ventricular
hypokinesia and competent valves.</p>
    <p>According to the patient, the dyspnea improved, but the palpitations remained.</p>
    <p>She reported a transient episode of speech difficulty and right hemiparesis in 2002. The
dyspnea reappeared, initially on moderate exertion and then on mild exertion.</p>
    <p>A new echocardiographic assessment detected marked tricuspid regurgitation.</p>
    <p>The medication was adjusted, with the prescription of the following drugs: warfarin, 5 mg;
losartan, 50 mg; furosemide, 80 mg; digoxin, 0.25 mg; and diltiazem, 180 mg.</p>
    <p>The symptoms improved, although episodes of aggravation occurred.</p>
    <p>In 2005, a new hemodynamic study revealed hypertension of the right chambers. Left
ventricular hypokinesia of moderate intensity in the inferior and apical walls, and of mild
intensity in the anterior wall, was identified.</p>
    <p>The pharmacological treatment was maintained, with adjustments according to symptoms. The
patient was brought to the hospital after 24 hours of vertigo, malaise and dyspnea.</p>
    <p>The physical examination on November 13, 2008, revealed pulse of 30 bpm, inaudible blood
pressure, crepitant rales in pulmonary bases, bradycardia, liver palpable 7 cm from the
costal margin, ascitis, and mild lower limb edema.</p>
    <p>The ECG revealed atrial fibrillation, high atrioventricular block and ventricular rate of
30 bpm.</p>
    <p>Chest X-ray showed enlarged cardiac area (+++/4+) and no signs of pulmonary congestion.</p>
    <p>The laboratory findings on that occasion were as follows: potassium, 4.4 mEq/L; sodium, 134
mEq/L; urea, 100 mg/dL; creatinine, 1.45 mg/L (glomerular filtration rate, 40
mL/min/1.73m<sup>2</sup>); INR, 2.6; BNP, 250 pg/mL; hemoglobin, 12.6 g/dL; hematocrit,
40%; leukocytes/mm<sup>3</sup>, 7900 (78% neutrophils, 10% lymphocytes, and 12% monocytes);
platelets/mm<sup>3</sup>, 183000; arterial lactate, 11 mg/dL; and blood digoxin level,
1.13 ng/mL.</p>
    <p>Atropine and dopamine were administered and blood volume, replaced, but with no heart rate
increase. Dobutamine was then administered, but unsuccessfully. A temporary transvenous
external pacemaker was implanted, after which, blood pressure increased to 106/60 mmHg.</p>
    <p>Permanent pacemaker was implanted on November, 19, 2008. The underlying disease posed
technical difficulty, and a reserve electrode was implanted in the coronary sinus for an
occasional capture loss of the right ventricular electrode.</p>
    <p>The laboratory findings on that occasion were as follows: hemoglobin, 9 g/dL; leukocytes,
4700/mm<sup>3</sup>; platelets, 114000/mm<sup>3</sup>; urea, 47 mg/dL; creatinine, 0.76
mg/dL; potassium, 4.6 mEq/L; sodium, 133 mEq/L; blood glucose, 122 mg/dL; hemoglobin, 11.8
g/dl; hematocrit, 36%; and lactate; 7 mg/dL.</p>
    <p>Oliguria and renal failure followed.</p>
    <p>On December 4, 2008, the laboratory findings were as follows: creatinine, 2.4 mg/dL; urea,
105 mg/dL; potassium, 5.3 mEq/L; sodium, 130 mEq/L; hemoglobin, 8.8 g/dL; hematocrit, 30%;
leukocytes, 6200/mm<sup>3</sup> (neutrophils 86%, lymphocytes 4%, and monocytes 10%);
platelets, 99000/mm<sup>3</sup>.</p>
    <p>The patient had ventricular fibrillation and cardiac arrest, which did not respond to the
resuscitation maneuvers, dying on December 5, 2008.</p>
    <sec>
      <title>Clinical aspects</title>
      <p>At the age of 29 years, the patient developed palpitations, which, after 5 years,
associated with dyspnea on exertion, which progressed slowly until the age of 39 years.
In young patients, the major causes of heart failure (HF) are idiopathic dilated
cardiomyopathy, myocarditis, Chagas disease, alcoholic cardiomyopathy, and, more rarely,
ischemic heart disease. In addition, rarer causes of HF in patients of tropical and
subtropical regions, such as EMF, are worthy of note.</p>
      <p>When the patient first sought the hospital, she was diagnosed with EMF, which is an
uncommon restrictive cardiomyopathy, accounting for 1.6% of the deaths due to cardiac
disease in Brazil<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. It is more common
in the eastern and central regions of Africa. Several cases have been reported in South
America and India, and sporadic ones have been reported worldwide. In some places, EMF
has an endemic distribution.</p>
      <p>Its etiology has not been completely clarified. Its pathogenesis is believed to involve
several factors, such as environmental exposure, nutritional and immune abnormalities,
in addition to genetic factors. One of the most accepted hypotheses is that of a more
advanced spectrum of Loeffler's disease, caused by eosinophilic infiltration of the
heart layers, with chronic inflammation and posterior fibrosis<sup><xref rid="r02" ref-type="bibr">2</xref>-<xref rid="r04" ref-type="bibr">4</xref></sup>. That pathogenic
process favors thrombosis, usually in the ventricular apex.</p>
      <p>The disease is characterized by deposition of fibrous tissue in the endocardium and, to
a lesser extent, in the myocardium, usually affecting the apical region of the right or
left ventricle, or both. A previous study has shown biventricular impairment in 50% of
the cases, of the left ventricle in 30%, and of the right ventricle in 27%<sup><xref rid="r02" ref-type="bibr">2</xref></sup>. In addition, EMF usually affects the
ventricular inlet, the papillary muscles and the valvular apparatus, mainly the mitral
valve<sup><xref rid="r03" ref-type="bibr">3</xref></sup>.</p>
      <p>In most patients, similarly to ours, the symptoms begin during adolescence, in the
second or third decades of life. The initial symptoms relate to diastolic dysfunction,
the systolic dysfunction being uncommon, except for the advanced stages of EMF<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. Ascitis can occur in 50% of the
patients, usually associated with important right ventricular fibrosis, worsening the
prognosis<sup><xref rid="r06" ref-type="bibr">6</xref></sup>. Our patient had
ascitis only in final stage of disease. Supraventricular arrhythmias can be observed in
60% of the patients, atrial fibrillation, as seen in our patient, being the most
common<sup><xref rid="r07" ref-type="bibr">7</xref></sup>.</p>
      <p>The diagnosis of EMF is established based on echocardiographic findings, which do not
correlate with the severity of symptoms. The most common echocardiographic findings are
changes in relaxation and compliance of the affected chamber, but usually without
enlargement of the ventricular volumes. The atria are often enlarged and dysfunctional.
Regurgitation of the atrioventricular valves is common. Pericardial effusion is usually
present, and can be important.</p>
      <p>Our patient's echocardiogram was compatible with the diagnosis of EMF, with marked
enlargement of the left atrium (57 mm) and preservation of the ventricular diameters.
Biventricular impairment with suggestive signs of calcification was observed.</p>
      <p>In addition, our patient underwent ventriculography, which confirmed the biventricular
involvement with mild mitral regurgitation. The hemodynamic study of patients with EMF
usually reveals elevation of the end-diastolic pressure of the ventricle affected,
restrictive pattern in the ventricular pressure recordings and obliteration of the
ventricular apex<sup><xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup>.</p>
      <p>The prognosis of EMF depends mainly on its clinical presentation. The following factors
are considered to worsen the prognosis: right ventricular impairment, ascitis, atrial
fibrillation, mitral insufficiency, and increased atrial, end-diastolic ventricular and
pulmonary pressures (&gt; 40 mm Hg). The major factor determining the prognosis,
however, is functional class (FC). A study has assessed survival according to the FC. Of
the patients with FC I and II, 85% survive two years<sup><xref rid="r08" ref-type="bibr">8</xref></sup>, while less than 30% of those with FC IV survive two
years<sup><xref rid="r10" ref-type="bibr">10</xref></sup>.</p>
      <p>Thus, the treatment of EMF is based on symptoms. The recommendation for patients with
few symptoms (FC I and II) is clinical treatment<sup><xref rid="r11" ref-type="bibr">11</xref></sup>, while that for more symptomatic ones [congestive HF (CHF) FC III
and IV] is surgical treatment<sup><xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref></sup>. In the presence of worse prognostic
factors, some experts recommend surgery already for FC II.</p>
      <p>Clinical treatment is extrapolated from the clinical treatment for diastolic HF, being
based on the following: diuretics to control blood volume; beta-blockers or calcium
channel blockers to control heart rate in patients with AF or atrial tachycardia; and
vitamin K antagonists for patients with intracardiac thrombi.</p>
      <p>Our patient had indication for those drugs, including anticoagulation, because she
already had had a thromboembolic event in 2002.</p>
      <p>The surgical treatment consists in resecting the area of endocardial fibrosis and in
correcting mitral or tricuspid regurgitation, when present, with valvular replacement or
repair.</p>
      <p>The initial surgical technique consists in replacing the impaired valves with
prostheses. Later studies have shown that valvoplasty with native valve preservation
related to lower morbidity and mortality.</p>
      <p>The mortality related to classical surgery is extremely high, ranging from 20% to
30%<sup><xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref></sup>; thus, whenever possible, the native valve should be
preserved.</p>
      <p>Surgery determines an important improvement in symptoms and survival in symptomatic
patients, and should always be performed in such patients.</p>
      <p>In 1999, Moraes et al<sup><xref rid="r14" ref-type="bibr">14</xref></sup> published a
study, assessing 83 patients submitted to surgery for EMF, 45% of whom had CHF, FC I and
II, and found a 55% survival in 17 years.</p>
      <p>Recurrence of valvular regurgitation after surgery is not rare, and many patients might
require a new surgery to fix the problem<sup><xref rid="r14" ref-type="bibr">14</xref></sup>.</p>
      <p>Moraes et al<sup><xref rid="r15" ref-type="bibr">15</xref></sup>, assessing 107 patients
undergoing surgery, have found a 4.5% incidence of fibrosis recurrence. The surgical
mortality related to reoperation in such cases was extremely high, reaching
50%<sup><xref rid="r15" ref-type="bibr">15</xref></sup>.</p>
      <p>Considering the high mortality associated with reoperation, the best treatment for that
group remains uncertain. The heart transplantation team of the Instituto do Cora&#xE7;&#xE3;o of
the Hospital das Cl&#xED;nicas of FMUSP has reported the good outcome and survival of one
patient with EMF previously submitted to surgery, but with recurrence of disease and
important symptoms of HF. The possibility that, for that group of patients, cardiac
transplantation can be more beneficial than reoperation has been raised<sup><xref rid="r16" ref-type="bibr">16</xref></sup>.</p>
      <p>In 1996, our patient underwent surgery for the resection of the endomyocardial fibrosis,
as well as mitral and tricuspid valvoplasty, because of important HF symptoms (FC III).
Initially, her symptoms improved, which was confirmed on the ventriculography performed
one month after surgery, showing competent valves and mild ventricular hypokinesia.</p>
      <p>A few years after surgery, the HF symptoms recurred and a new echocardiogram showed
important tricuspid regurgitation. A new hemodynamic study was performed in 2005,
showing hypertension of the right chambers and moderate left ventricular hypokinesia,
raising the suspicion of disease relapse. On the occasion, clinical treatment was
chosen, but performing some tests, such as cardiac magnetic resonance, could have helped
to establish the diagnosis of disease relapse.</p>
      <p>The presence of hypertension of the right chambers could be related to HF itself,
pulmonary thromboembolism, chronic obstructive pulmonary disease or other causes,
requiring further investigation.</p>
      <p>The patient's symptoms worsened and, on November 13, 2008, she sought the hospital with
cardiogenic shock and important bradycardia, requiring transvenous pacemaker
implantation. That bradycardia could have been caused by the use of medications to
control heart rate, diltiazem and digoxin, because the fibrotic impairment of the
cardiac conduction system is not common in EMF.</p>
      <p>Despite all hemodynamic support and initial improvement, the patient's renal function
worsened, raising the suspicion that her most likely cause of death was cardiogenic
shock secondary to EMF relapse with valvular impairment.</p>
      <p>The retrospective analysis of this case raised doubt whether a new surgery or heart
transplantation in 2005, when the patient's CHF symptoms recurred, would have changed
the disease course.</p>
      <p>Further studies are required to help deciding on the best treatment for EMF relapse.</p>
      <p>
<bold>(Michel Abi Kalansky Ponczek, MD, and Fernanda Seligmann Feitosa, MD)</bold>
</p>
      <p><bold>Diagnostic hypothesis:</bold> Endomyocardial fibrosis</p>
      <p>(Michel Abi Kalansky Ponczek, MD, and Fernanda Seligmann Feitosa, MD)</p>
    </sec>
    <sec>
      <title>Postmortem examination</title>
      <p>The heart weighed 652 g (normal: 200-300 g) and had multiple adherences between the
visceral and parietal pericardium. Its volume was enlarged, especially because of the
atria, whose volume was proportionally greater than that of the ventricles (<xref ref-type="fig" rid="f02">Figure 2A</xref>). Opening of the heart revealed marked
atrial dilatation and bilateral moderate endocardial thickening. The rings of the mitral
and tricuspid valves showed surgical sutures of older valvoplasties, close to the
insertion of the posterior cusps (<xref ref-type="fig" rid="f02">Figure 2B</xref>). The
right atrial roof also showed an old surgical suture. Endocardial thickening with areas
of calcification was more intense in the ventricular inlet and apices, but partial in
the left ventricular outflow tract, sparing the right ventricular outflow tract (<xref ref-type="fig" rid="f03">Figure 3</xref>). The myocardial trabeculae were bound
together due to endocardial thickening, which also involved the papillary muscles of the
mitral and tricuspid valves, with marked reduction of the ventricular cavities and
amputation of the ventricular tips (<xref ref-type="fig" rid="f03">Figure 3</xref>). The
chordae tendineae and cusps of the atrioventricular valves were not affected by
endocardial thickening; however, there was moderate retraction of the free margins of
the cusps and bilateral dilatation of the valvular ring. The right ventricular
endocardium showed implanted electrodes of permanent biventricular cardiac pacemaker:
one in the middle third of the interventricular septum and another in the anterolateral
wall. There was thrombus on neither the pacemaker leads nor their implantation sites. On
gross examination, no thrombi were found in the cardiac cavities, and the
ventriculoarterial valves showed no abnormalities. The epicardial coronary arteries had
no important obstructive changes. The microscopic examination revealed intense
endocardial fibrosis and calcification, neovascularization areas and sparse
lymphomononuclear inflammatory infiltrate, with expansion of irregular fibrous bands to
the subjacent myocardium (<xref ref-type="fig" rid="f04">Figure 4</xref>). Eosinophils
were present in neither the endocardial inflammatory infiltrate nor other organs. The
kidneys showed multiple and extensive healed cortical infarctions. In addition,
morphological changes due to CHF, such as diffuse edema of the subcutaneous tissue,
ascitis (1500 mL of yellow hyaline fluid) and chronic passive congestion in the lungs,
liver and spleen, were observed. The cause of death was low cardiac output secondary to
CHF, histologically represented by acute tubular necrosis and centrilobular necrosis of
the liver.</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>A - Heart, diaphragmatic surface: atrial volumes are proportionally greater than
the ventricular ones. The right coronary artery is found in the atrioventricular
sulcus (**), and the posterior interventricular branch of the right coronary
artery, in the posterior ventricular sulcus (*). B - Left and right atria:
bilateral endocardial thickening and surgical sutures of the old valvoplasty
(arrows) in the posterior cusps (arrows) of the mitral (M) and tricuspid (T)
valves.</p>
        </caption>
        <graphic xlink:href="abc-105-03-0309-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <p>A and B - Right ventricular inlet and outflow tract: endocardial fibrosis
affecting the ventricular inlet (arrows), with amputation of the ventricular apex
(yellow dotted line), but sparing the outflow tract. C and D - Left ventricular
inlet and outflow tract: endocardial fibrosis affecting the ventricular inlet and
the papillary muscles of the mitral valve (arrows), amputation of the left
ventricular apex (yellow dotted line) and extension to the ventricular outflow
tract, but sparing the aortic valve (Ao).</p>
        </caption>
        <graphic xlink:href="abc-105-03-0309-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Endomyocardial photomicrograph: A - Organizing thrombus (tr) on the endocardium
with intense fibrosis (f) (Hematoxylin-Eosin, 25x). B - Neovascularization and
lymphoplasmacytic and mononuclear inflammatory infiltrate (between arrows) amid
endomyocardial fibrosis, with calcified area (ca); m- myocardium (Hematoxylin
Eosin, 25x). C - Irregular fibrosis bands (blue) surrounding cardiomyocytes (red)
in the subendocardial region (Masson trichrome, 50x).</p>
        </caption>
        <graphic xlink:href="abc-105-03-0309-g04"/>
      </fig>
      <p>
<bold>(L&#xE9;a Maria Macruz Ferrreira Demarchi, MD)</bold>
</p>
      <p>
<bold>Anatomopathological diagnoses:</bold>
</p>
      <p>1) Biventricular endomyocardial fibrosis, operated on; 2) Congestive heart failure; 3)
Low cardiac output.</p>
      <p>
<bold>(L&#xE9;a Maria Macruz Ferrreira Demarchi, MD)</bold>
</p>
    </sec>
    <sec>
      <title>Comments</title>
      <p>The cardiac lesions revealed on the postmortem examination describe the morphology of
biventricular EMF. The major characteristic of EMF is the focal or diffuse thick
endocardial fibrosis, which affects mainly the inlet and apical region of one or both
ventricles<sup><xref rid="r17" ref-type="bibr">17</xref></sup>. The myocardial
trabeculae can be bound together due to endocardial thickening, which can involve the
papillary muscle, chordae tendineae and the cusps of the atrioventricular valves,
causing valvular insufficiency. Although our patient had already undergone mitral and
tricuspid valvoplasty, such valves still had morphological changes of insufficiency,
such as valvular ring dilatation and retraction of the free margin of the cusps.
Microscopically, EMF is represented by dense and collagen endocardial fibrosis, with
fragmented and irregularly arranged elastic fibers, which affect the subjacent
myocardium, whose close regions have vascular neoformation and a variable amount of
lymphoplasmacytic and mononuclear inflammatory infiltrate, with or without
eosinophils<sup><xref rid="r18" ref-type="bibr">18</xref></sup>. Although not
always present, eosinophils in endocardial lesions and peripheral eosinophilia, observed
in different studies of individuals with EMF, have been reported as one of the probable
causes of that disease<sup><xref rid="r19" ref-type="bibr">19</xref></sup>, whose
etiopathogenesis remains to be clarified<sup><xref rid="r20" ref-type="bibr">20</xref></sup>. Several authors have proposed that the eosinophilic form, also
known as Loeffler's endocarditis, and EMF without eosinophils represent different stages
of the same disease, because the morphological endocardial changes in the chronic stage
cannot be differentiated in the patients with and without eosinophilia<sup><xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref></sup>. This can be seen in our patient, who had eosinophils in neither the
endocardial inflammatory infiltrate nor other organs. As EMF progresses, the formation
and organization of endocardial thrombosis contribute to the obliteration and reduction
of the ventricular cavity, and advanced cases frequently show calcification amid the
fibrosis<sup><xref rid="r18" ref-type="bibr">18</xref></sup>. Usually, atrial
dilatation results from the ventricular restriction caused by the endomyocardial
fibrosis and the mitral and tricuspid valvular insufficiency, as well as from the
pulmonary vascular changes secondary to passive pulmonary congestion, as reported in our
patient. The healed renal infarctions were very likely caused by embolism from the
previous thrombosis in the left ventricle. It is worth noting the post-surgery 12-year
survival of our patient, considering the extension of the EMF lesions found on the
postmortem examination. The survival likelihood of patients with EMF submitted to
surgery is approximately 70% ten years after surgery<sup><xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref></sup>. Such lesions very
likely represent disease relapse, but the possibility that not all the tissue affected
by EMF had been removed in the previous surgery should be kept in mind.</p>
      <p>
<bold>(L&#xE9;a Maria Macruz Ferrreira Demarchi, MD)</bold>
</p>
      <p><bold>Section editor:</bold> Alfredo Jos&#xE9; Mansur
(<email>ajmansur@incor.usp.br</email>)</p>
      <p><bold>Associated editors:</bold> Desid&#xE9;rio Favarato
(<email>dclfavarato@incor.usp.br</email>)</p>
      <p>Vera Demarchi Aiello (<email>anpvera@incor.usp.br</email>)</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Guimar&#xE3;es</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <chapter-title>Natural history and current status in Brazil</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Vatalian</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Sommers</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kartha</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <source>Endomyocardial fibrosis</source>
          <publisher-loc>Oxford</publisher-loc>
          <publisher-name>Oxford University Press</publisher-name>
          <year>1993</year>
          <fpage>37</fpage>
          <lpage>54</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pileggi</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Endomyocardial fibrosis. Longitudinal followup
of patients not treated with surgery</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1996</year>
          <volume>67</volume>
          <issue>4</issue>
          <fpage>285</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="pmid">9181730</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Wynne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <chapter-title>The cardiomyopathies and myocardites</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <source>Heart disease: a textbook of cardiovascular medicine</source>
          <edition>5th ed</edition>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>WB Saunders Co</publisher-name>
          <fpage>1780</fpage>
          <lpage>1783</lpage>
          <year>1997</year>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vianna Cde</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Correlation between eosinophilia and endomyocardial fibrosis. Current
status</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1990</year>
          <volume>54</volume>
          <issue>4</issue>
          <fpage>247</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="pmid">2275625</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brindeiro Filho</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cavalcanti</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Value of Doppler echocardiography in the diagnosis and management of
endomyocardial fibrosis</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1996</year>
          <volume>67</volume>
          <issue>4</issue>
          <fpage>279</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="pmid">9181729</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dal B&#xF3;</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Clinical meaning of ascites in patients with endomyocardial
fibrosis</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2002</year>
          <volume>78</volume>
          <issue>2</issue>
          <fpage>196</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">11887195</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nussbacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ianni</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Jatene</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atrial fibrillation in endomyocardial fibrosis is a marker of worse
prognosis</article-title>
          <source>Int J Cardiol</source>
          <year>1998</year>
          <volume>67</volume>
          <issue>1</issue>
          <fpage>19</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">9880197</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>da Luz</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Stolf</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Determinants of survival in endomyocardial fibrosis</article-title>
          <source>Circulation</source>
          <year>1989</year>
          <volume>80</volume>
          <issue>3</issue>
          <issue-part>Pt 1</issue-part>
          <fpage>I177</fpage>
          <lpage>I182</lpage>
          <pub-id pub-id-type="pmid">2766524</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bersano</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Zago</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Reali</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Hemodynamic and cineangiographic study in patients with primary
endomyocardiopathy of the obliterative type</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1979</year>
          <volume>32</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">464846</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Maximal functional capacity in patients with endomyocardial
fibrosis</article-title>
          <source>Eur Heart J</source>
          <year>1993</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>240</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="pmid">8449201</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pileggi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Endomyocardial fibrosis: longitudinal follow-up of patients not
treated with surgery</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1996</year>
          <volume>67</volume>
          <issue>4</issue>
          <fpage>285</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="pmid">9181730</pub-id>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Barreto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>B&#xF3;</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Stolf</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Arteaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <source>Cirurgia para endomiocardiofibrose melhora a qualidade de vida e a
preserva&#xE7;&#xE3;o das v&#xE1;lvulas reduzem a morbidade e mortalidade</source>
          <conf-name>Tema livre do LIII Congresso Brasileiro de Cardiologia</conf-name>
          <comment>Resumo dispon&#xED;vel no endere&#xE7;o eletr&#xF4;nico: <ext-link ext-link-type="uri" xlink:href="http://educacao.cardiol.br/congresso/liii/temas/336.asp">http://educacao.cardiol.br/congresso/liii/temas/336.asp</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Dallan</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Mady</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jatene</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Endomyocardial fibrosis surgery with atrioventricular valve
preservation</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1996</year>
          <volume>67</volume>
          <issue>4</issue>
          <fpage>289</fpage>
          <lpage>295</lpage>
          <pub-id pub-id-type="pmid">9181731</pub-id>
        </element-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moraes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lapa</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hazin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tenorio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Surgery for endomyocardial fibrosis revisited</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <year>1999</year>
          <volume>15</volume>
          <issue>3</issue>
          <fpage>309</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="pmid">10333028</pub-id>
        </element-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moraes</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Buffolo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Moraes Neto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Branco</surname>
              <given-names>JN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recurrence of fibrosis after endomyocardial fibrosis
surgery</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1996</year>
          <volume>67</volume>
          <issue>4</issue>
          <fpage>297</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">9181732</pub-id>
        </element-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Freitas</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>de Castro</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Chizzola</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Heart transplantation in a patient with endomyocardial
fibrosis</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2005</year>
          <volume>84</volume>
          <issue>1</issue>
          <fpage>49</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">15841846</pub-id>
        </element-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connor</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Somers</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hutt</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Manion</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>D'Arbela</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Endomyocardial fibrosis in Uganda (Davies' disease). 1. An
epidemiologic, clinical and pathologic study</article-title>
          <source>Am Heart J</source>
          <year>1967</year>
          <volume>74</volume>
          <issue>5</issue>
          <fpage>687</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="pmid">4861733</pub-id>
        </element-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connor</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Somers</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hutt</surname>
              <given-names>MSR</given-names>
            </name>
            <name>
              <surname>Manion</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>D'Arbela</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Endomyocardial fibrosis (Davies' disease). II. An epidemiologic,
clinical and pathologic study</article-title>
          <source>Am Heart J</source>
          <year>1968</year>
          <volume>75</volume>
          <issue>1</issue>
          <fpage>107</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">4229457</pub-id>
        </element-citation>
      </ref>
      <ref id="r19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parrillo</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Borer</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Fauci</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>The cardiovascular manifestations of the hypereosinophilic syndrome.
Prospective study of 26 patients, with review of the literature</article-title>
          <source>Am J Med</source>
          <year>1979</year>
          <volume>67</volume>
          <issue>4</issue>
          <fpage>572</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="pmid">495628</pub-id>
        </element-citation>
      </ref>
      <ref id="r20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mocumbi</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Endomyocardial fibrosis: a form of endemic restrictive
cardiomyopathy</article-title>
          <source>Glob Cardiol Sci Pract</source>
          <year>2012</year>
          <volume>2012</volume>
          <issue>1</issue>
          <fpage>11</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">25610842</pub-id>
        </element-citation>
      </ref>
      <ref id="r21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brockington</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>L&#xF6;ffler's endocarditis and Davies' endomyocardial
fibrosis</article-title>
          <source>Am Heart J</source>
          <year>1973</year>
          <volume>85</volume>
          <fpage>308</fpage>
          <lpage>322</lpage>
        </element-citation>
      </ref>
      <ref id="r22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roberts</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Ferrans</surname>
              <given-names>VJ</given-names>
            </name>
          </person-group>
          <article-title>Pathologic anatomy of the cardiomyopathies - idiopathic dilated and
hypertrophic types, infiltrative types, and endomyocardial disease with and
without eosinophilia</article-title>
          <source>Human Pathol</source>
          <year>1975</year>
          <volume>6</volume>
          <issue>3</issue>
          <fpage>287</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">124302</pub-id>
        </element-citation>
      </ref>
      <ref id="r23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schneider</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Jenny</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Turina</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Turina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>OM</given-names>
            </name>
          </person-group>
          <article-title>Long-term follow up of patients with endomyocardial fibrosis: effects
of surgery</article-title>
          <source>Heart</source>
          <year>1998</year>
          <volume>79</volume>
          <issue>4</issue>
          <fpage>362</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">9616343</pub-id>
        </element-citation>
      </ref>
      <ref id="r24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moraes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lapa</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hazin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tenorio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Surgery for endomyocardial fibrosis revisited</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <year>1999</year>
          <volume>15</volume>
          <issue>3</issue>
          <fpage>309</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="pmid">10333028</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
